ALK/ROS1 rearrangements: A real hallmark for thromboembolic events in cancer patients?

被引：6
|
作者：
Nichetti, Federico [1 ]
Lo Russo, Giuseppe [1 ]
Prelaj, Arsela [1 ]
Provenzano, Leonardo [1 ]
de Braud, Filippo [1 ,2 ]
Cabiddu, Mary [3 ]
Garassino, Marina Chiara [1 ]
Petrelli, Fausto [3 ]
机构：
[1] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Via Venezian 1, I-20133 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
[3] ASST Bergamo Ovest, Med Oncol Unit, I-24047 Treviglio, BG, Italy
来源：
THROMBOSIS RESEARCH | 2020年 / 194卷
关键词：
Non-Small-Cell Lung Cancer; Thromboembolic events; Thrombosis; ALK; ROS-1; Tyrosine kinase inhibitors; VENOUS THROMBOEMBOLISM;
D O I：
10.1016/j.thromres.2020.06.041
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：176 / 177
页数：2
相关论文
共 50 条
  • [21] ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFRWild Type Lung Adenocarcinoma - A Multicenter Study of 732 Cases
    Song, Zhengbo
    Zheng, Yuhui
    Zhang, Yiping
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1160 - S1161
  • [22] Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System
    Hernandez, Susana
    Conde, Esther
    Prieto, Mario
    Martinez, Rebeca
    Rodriguez, Margarita
    Martin, Raquel
    Jimenez, Luis
    Madrigal, Luis
    Angulo, Barbara
    Lopez-Rios, Fernando
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S513 - S514
  • [23] A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer
    Alexander, Marliese
    Pavlakis, Nick
    John, Thomas
    O'Connell, Rachel
    Kao, Steven
    Hughes, Brett G. M.
    Lee, Adrian
    Hayes, Sarah A.
    Howell, Viive M.
    Clarke, Stephen J.
    Millward, Michael
    Burbury, Kate
    Solomon, Benjamin
    Itchins, Malinda
    LUNG CANCER, 2020, 142 : 34 - 40
  • [24] ALK and ROS1 Overexpression is Very Rare in Colorectal Adenocarcinoma
    Houang, Michelle
    Toon, Christopher W.
    Clarkson, Adele
    Sioson, Loretta
    de Silva, Keshani
    Watson, Nicole
    Singh, Nisha R.
    Chou, Angela
    Gill, Anthony J.
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2015, 23 (02) : 134 - 138
  • [25] ALK, ROS1, and RET - Does the Partner Gene Matter?
    Lovly, Christine
    Childress, Merrida
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S128 - S129
  • [26] Multicenter Evaluation of a Novel ROS1 Immunohistochemistry Assay (SP384) for Detection of ROS1 Rearrangements in a Large Cohort of Lung Adenocarcinoma Patients
    Hofman, Veronique
    Rouquette, Isabelle
    Long-Mira, Elodie
    Piton, Nicolas
    Chamorey, Emmanuel
    Heeke, Simon
    Vignaud, Jean Michel
    Yguel, Clemence
    Mazieres, Julien
    Lepage, Anne-Laure
    Bibeau, Frederic
    Begueret, Hugues
    Lassalle, Sandra
    Lalvee, Salome
    Zahaf, Katia
    Benzaquen, Jonathan
    Poudenx, Michel
    Marquette, Charles-Hugo
    Sabourin, Jean-Christophe
    Ilie, Marius
    Hofman, Paul
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : 1204 - 1212
  • [27] Real-World Experience on Treatment of crizotinib in ALK/ROS1/MET Alterated Non-Small-Cell Lung Cancer Patients in China
    Yang, S.
    Wu, K.
    Chen, X.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1091 - S1091
  • [28] Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions
    Desilets, Antoine
    Repetto, Matteo
    Yang, Soo-Ryum
    Drilon, Alexander
    CANCER, 2025, 131
  • [29] Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)
    Janzic, Urska
    Maimon Rabinovich, Natalie
    Shalata, Walid
    Kian, Waleed
    Szymczak, Katarzyna
    Dziadziuszko, Rafal
    Jakopovic, Marko
    Mountzios, Giannis
    Pluzanski, Adam
    Araujo, Antonio
    Charpidou, Andriani
    Daher, Sameh
    Agbarya, Abed
    CURRENT ONCOLOGY, 2024, 31 (08) : 4369 - 4381
  • [30] LORLATINIB ALK/ROS1 inhibitor Treatment of non-small cell lung cancer
    Gajdosik, Z.
    DRUGS OF THE FUTURE, 2016, 41 (12) : 715 - 723
12345